Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26405354 | 0.92 | GNAI3 (0.38) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25480274 | 0.91 | GNAI3 (0.39) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25707631 | 0.90 | GNAI3 (0.40) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25833597 | 0.88 | GNAI3 (0.40) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL23696468 | 0.88 | GNAI3 (0.37) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25829585 | 0.88 | MAPT (0.39) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL23945313 | 0.85 | GNAI3 (0.40) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25728795 | 0.84 | GNAI3 (0.39) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25884459 | 0.84 | GNAI3 (0.38) | GNAI3GNAI1GNAO1MEN1KMT2A | |
| SCHEMBL25888291 | 0.82 | MAPT (0.35) | GNAI3GNAI1GNAO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAI1 1458/4885GNAO1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.